ABSTRACT
The TANGO study (ClinicalTrials.gov, NCT03446573) demonstrated that switching to dolutegravir/lamivudine (DTG/3TC) was non-inferior to continuing tenofovir alafenamide-based regimens (TBR) through week 144. Retrospective baseline proviral DNA genotypes were performed for 734 participants (post-hoc analysis) to assess the impact of archived, pre-existing drug resistance on 144-week virologic outcomes by last on-treatment viral load (VL) and Snapshot. A total of 320 (86%) participants on DTG/3TC and 318 (85%) on TBR had both proviral genotype data and ≥1 on-treatment post-baseline VL results and were defined as the proviral DNA resistance analysis population. Archived International AIDS Society-USA major nucleoside reverse transcriptase inhibitor, non-nucleoside reverse transcriptase inhibitor, protease inhibitor, and integrase strand transfer inhibitor resistance-associated mutations (RAMs) were observed in 42 (7%), 90 (14%), 42 (7%), and 11 (2%) participants, respectively, across both groups; 469 (74%) had no major RAMs at baseline. M184V/I (1%), K65N/R (<1%), and thymidine analogue mutations (2%) were infrequent. Through week 144, >99% of participants on DTG/3TC and 99% on TBR were virologically suppressed (last on-treatment VL <50 copies/mL) regardless of the presence of major RAMs. Results from the sensitivity analysis by Snapshot were consistent with the last available on-treatment VL. In TANGO, archived, pre-existing major RAMs did not impact virologic outcomes through week 144.
Subject(s)
Anti-HIV Agents , HIV Infections , HIV Seropositivity , HIV-1 , Humans , Lamivudine/therapeutic use , Reverse Transcriptase Inhibitors/therapeutic use , HIV Infections/drug therapy , HIV-1/genetics , Retrospective Studies , Treatment Outcome , Heterocyclic Compounds, 3-Ring/therapeutic use , Anti-HIV Agents/therapeutic use , Viral LoadABSTRACT
No disponible
Subject(s)
Humans , Male , Middle Aged , Antitubercular Agents/pharmacology , Antitubercular Agents/administration & dosage , Morocco , SpainSubject(s)
Frailty , HIV Infections , Fever/etiology , HIV Infections/complications , HIV Infections/drug therapy , Humans , Myalgia/etiologyABSTRACT
BACKGROUND: Strongyloidiasis is a disease of great public health significance, caused by the parasitic nematodes Strongyloides stercoralis, Strongyloides fuelleborni, and Strongyloides fuelleborni subsp. kellyi. This systematic review and meta-analysis aimed to assess the prevalence of Strongyloides stercoralis infection in Peru. METHODS: The review was based on a literature search in PubMed, SciELO and Google Scholar using the key words or root words "strongyl*" AND "Peru" on 15 July 2020. Eligible studies were published from 1 January 1981 to 15 July 2020 and written in English, Spanish, Italian, or French. RESULTS: We included 21 papers in the analysis. Studies were heterogeneous in terms of study population and diagnostic methods (e.g. Baermann technique, agar, Dancescu or charcoal cultures, serology, string capsule). Prevalence of S. stercoralis ranged from 0.3 to 45%. The pooled proportion of Strongyloides in the general population was 7.34% (95% CI 4.97 to 10.13%). Half the studies were designed to detect parasites in general. In studies designed to detect S. stercoralis, the most widely used diagnostic method was the Baermann technique. CONCLUSION: Prevalence of S. stercoralis in Peru was high but varied by geographic area, techniques for stool examination, and participant characteristics.
Subject(s)
Strongyloides stercoralis , Strongyloidiasis , Animals , Feces , Humans , Peru/epidemiology , Prevalence , Strongyloidiasis/diagnosis , Strongyloidiasis/epidemiologyABSTRACT
INTRODUCTION: Tocilizumab (TCZ) is an interleukin-6 receptor antagonist, which has been used for the treatment of severe SARS-CoV-2 pneumonia (SSP), which aims to ameliorate the cytokine release syndrome (CRS) induced acute respiratory distress syndrome (ARDS). However, there are no consistent data about who might benefit most from it. METHODS: We administered TCZ on a compassionate-use basis to patients with SSP who were hospitalized (excluding intensive care and intubated cases) and who required oxygen support to have a saturation >93%. The primary endpoint was intubation or death after 24 h of its administration. Patients received at least one dose of 400 mg intravenous TCZ from March 8, 2020 to April 20, 2020. RESULTS: A total of 207 patients were studied and 186 analyzed. The mean age was 65 years and 68% were male patients. A coexisting condition was present in 68% of cases. Prognostic factors of death were older age, higher IL-6, d-dimer and high-sensitivity C-reactive protein (HSCRP), lower total lymphocytes, and severe disease that requires additional oxygen support. The primary endpoint (intubation or death) was significantly worst (37% vs 13%, p < 0·001) in those receiving the drug when the oxygen support was high (FiO2 >0.5%). CONCLUSIONS: TCZ is well tolerated in patients with SSP, but it has a limited effect on the evolution of cases with high oxygen support needs.
Subject(s)
Antibodies, Monoclonal, Humanized/administration & dosage , COVID-19 Drug Treatment , Adult , Aged , Aged, 80 and over , C-Reactive Protein/immunology , COVID-19/immunology , COVID-19/mortality , COVID-19/virology , Compassionate Use Trials , Critical Care/statistics & numerical data , Female , Humans , Immunologic Factors , Interleukin-6/immunology , Male , Middle Aged , SARS-CoV-2/drug effects , SARS-CoV-2/physiology , SpainABSTRACT
BACKGROUND: Long-acting (LA) injectable regimens are a potential therapeutic option in people living with HIV-1. SETTING: ATLAS (NCT02951052) and FLAIR (NCT02938520) were 2 randomized, open-label, multicenter, multinational phase 3 studies. METHODS: Adult participants with virologic suppression (plasma HIV-1 RNA <50 copies/mL) were randomized (1:1) to continue with their current antiretroviral regimen (CAR) or switch to the long-acting (LA) regimen of cabotegravir (CAB) and rilpivirine (RPV). In the LA arm, participants initially received oral CAB + RPV once-daily for 4 weeks to assess individual safety and tolerability, before starting monthly injectable therapy. The primary endpoint of this combined analysis was antiviral efficacy at week 48 (FDA Snapshot algorithm: noninferiority margin of 4% for HIV-1 RNA ≥50 copies/mL). Safety, tolerability, and confirmed virologic failure (2 consecutive plasma HIV-1 RNA ≥200 copies/mL) were secondary endpoints. RESULTS: The pooled intention-to-treat exposed population included 591 participants in each arm [28% women (sex at birth), 19% aged ≥50 years]. Noninferiority criteria at week 48 were met for the primary (HIV-1 RNA ≥50 copies/mL) and key secondary (HIV-1 RNA <50 copies/mL) efficacy endpoints. Seven individuals in each arm (1.2%) developed confirmed virologic failure; 6/7 (LA) and 3/7 (CAR) had resistance-associated mutations. Most LA recipients (83%) experienced injection site reactions, which decreased in incidence over time. Injection site reactions led to the withdrawal of 6 (1%) participants. The serious adverse event rate was 4% in each arm. CONCLUSION: This combined analysis demonstrates monthly injections of CAB + RPV LA were noninferior to daily oral CAR for maintaining HIV-1 suppression.
Subject(s)
Anti-HIV Agents/administration & dosage , Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , HIV-1 , Rilpivirine/administration & dosage , Rilpivirine/therapeutic use , Adult , Aged , Anti-HIV Agents/adverse effects , Delayed-Action Preparations , Drug Combinations , Female , Humans , Male , Middle Aged , Rilpivirine/adverse effects , Young AdultABSTRACT
Aims: To assess the prevalence of Chagas disease in pregnant women in Iquitos City, Peru. Material and Methods: Cross-sectional survey in 300 pregnant women in Iquitos (Peru) from 1 May 2019 to 15 June 2019. Women were tested using an ELISA serology test. Results: Serology was positive in one case (prevalence: 0.33%; 95% confidence interval: 7.1-13.9%), of a 25-year-old woman who lived in a wooden house with a leaf roof in a periurban area of Iquitos. She was familiar with kissing bugs and had chronic, asymptomatic Chagas disease. Conclusion: The prevalence of Chagas disease is low in the urban and peri-urban area of the city of Iquitos.
ABSTRACT
Strongyloidiasis is a soil-transmitted helminthiasis with a high global prevalence. OBJECTIVES: We aimed to evaluate the prevalence of Strongyloides stercoralis infection and assess strongyloidiasis serology as a screening technique in the Peruvian Amazon. MATERIAL AND METHODS: We performed a cross-sectional study of strongyloidiasis in 300 pregnant women in Iquitos (Peru) from 1 May 2019 to 15 June 2019. Women were tested using serology (Strongyloides IgG IVD-ELISA kit) as an index test and the modified Baermann technique and/or charcoal fecal culture as the parasitological reference standard. RESULTS: The reference tests showed S. stercoralis in the stool of 30 women (prevalence: 10%; 95% confidence interval [CI] 7.1% to 13.9%), while 101 women tested positive on the blood test (prevalence: 33.7%; 95% CI 28.6% to 39.4%). Fourteen of the 15 women (93.3%) with positive results according to the modified Baermann technique, and 14 of the 23 women (56.5%) with positive charcoal cultures also had positive serological results. Serology showed a sensitivity of 63.3% and a negative predictive value of 94.4%. CONCLUSION: In Iquitos, pregnant women have a high prevalence of S stercoralis. S. stercoralis ELISA could be an excellent tool for population-based screening, as it has a high negative predictive value that can help to rule out the presence of active infection.
ABSTRACT
BACKGROUND: Long-acting injectable regimens may simplify therapy for patients with human immunodeficiency virus type 1 (HIV-1) infection. METHODS: We conducted a phase 3, randomized, open-label trial in which adults with HIV-1 infection who had not previously received antiretroviral therapy were given 20 weeks of daily oral induction therapy with dolutegravir-abacavir-lamivudine. Participants who had an HIV-1 RNA level of less than 50 copies per milliliter after 16 weeks were randomly assigned (1:1) to continue the current oral therapy or switch to oral cabotegravir plus rilpivirine for 1 month followed by monthly injections of long-acting cabotegravir plus rilpivirine. The primary end point was the percentage of participants who had an HIV-1 RNA level of 50 copies per milliliter or higher at week 48 (Food and Drug Administration snapshot algorithm). RESULTS: At week 48, an HIV-1 RNA level of 50 copies per milliliter or higher was found in 6 of 283 participants (2.1%) who received long-acting therapy and in 7 of 283 (2.5%) who received oral therapy (adjusted difference, -0.4 percentage points; 95% confidence interval [CI], -2.8 to 2.1), a result that met the criterion for noninferiority for the primary end point (margin, 6 percentage points). An HIV-1 RNA level of less than 50 copies per milliliter at week 48 was found in 93.6% who received long-acting therapy and in 93.3% who received oral therapy (adjusted difference, 0.4 percentage points; 95% CI, -3.7 to 4.5), a result that met the criterion for noninferiority for this end point (margin, -10 percentage points). Of the participants who received long-acting therapy, 86% reported injection-site reactions (median duration, 3 days; mild or moderate severity, 99% of cases); 4 participants withdrew from the trial for injection-related reasons. Grade 3 or higher adverse events and events that met liver-related stopping criteria occurred in 11% and 2%, respectively, who received long-acting therapy and in 4% and 1% who received oral therapy. Treatment satisfaction increased after participants switched to long-acting therapy; 91% preferred long-acting therapy at week 48. CONCLUSIONS: Therapy with long-acting cabotegravir plus rilpivirine was noninferior to oral therapy with dolutegravir-abacavir-lamivudine with regard to maintaining HIV-1 suppression. Injection-site reactions were common. (Funded by ViiV Healthcare and Janssen; FLAIR ClinicalTrials.gov number, NCT02938520.).
Subject(s)
Anti-HIV Agents/administration & dosage , HIV Infections/drug therapy , HIV-1/isolation & purification , Pyridones/administration & dosage , Rilpivirine/administration & dosage , Administration, Oral , Adult , Anti-HIV Agents/adverse effects , Anti-HIV Agents/blood , Anti-Retroviral Agents/therapeutic use , CD4 Lymphocyte Count , Drug Resistance, Viral/genetics , Drug Therapy, Combination , Female , HIV-1/genetics , Humans , Induction Chemotherapy , Injections, Intramuscular , Maintenance Chemotherapy , Male , Middle Aged , Mutation , Patient Reported Outcome Measures , Pyridones/adverse effects , Pyridones/blood , RNA, Viral/blood , Rilpivirine/adverse effects , Rilpivirine/blood , Viral LoadABSTRACT
Introducción. La enseñanza de la medicina tropical, salud internacional o salud global en las Facultades de Medicina y Farmacia españolas se desconoce. El objetivo de este estudio es mostrar el panorama actual de la docencia en grado y post-grado. Material y métodos. Se revisan los planes de estudio, identificando aquellas asignaturas y postgrados con la denominación "Medicina Tropical", "Salud Internacional", "Salud Global" o "Enfermedades Importadas". Resultados. En 15 de las 40 (37,5 %) facultades de Medicina se imparte durante el grado la materia de Medicina Tropical, Salud Internacional o Salud Global. En 14 de ellas (93,3%) con carácter optativo y en 1 (6,7%) con carácter obligatorio. En 4 de las 22 (18,1%) facultades de Farmacia se imparte en el grado la materia de medicina tropical, salud internacional o salud global. Conclusión. La docencia en Medicina Tropical, Salud Internacional y Salud Global en las facultades de Medicina y Farmacia tienen una presencia limitada actualmente
Background. The teaching of tropical medicine, international health or global health in the Spanish Schools of Medicine and Pharmacy is unknown. The objective of this study is to show a current overview of teaching in degree and post-graduate. Material and methods. The curricula are reviewed, identifying those subjects and postgraduate courses with the denomination "Tropical Medicine", "International Health", "Global Health" or "Imported Diseases" Results. In 15 of the 40 (37.5%) schools of Medicine the subject of Tropical Medicine, International Health or Global Health is taught during the degree. In 14 of them (93.3%) with an optional character and in one (6.7%) with obligatory character. In 4 out of 22 (18.1%) Pharmacy schools are taught in the degree of Tropical Medicine, International Health or Global Health. Conclusions. The teaching in Tropical Medicine, International Health and Global Health in the Schools of Medicine and Pharmacy in Spain has, currently, a limited presence
Subject(s)
Humans , Global Health/education , Tropical Medicine/education , Universities/statistics & numerical data , Curriculum , Education, Medical, Continuing/statistics & numerical data , Schools, Medical , Spain , Students, Medical , TeachingABSTRACT
In a global world, knowledge of imported infectious diseases is essential in daily practice, both for the microbiologist-parasitologist and the clinician who diagnoses and treats infectious diseases in returned travelers. Tropical and subtropical countries where there is a greater risk of contracting an infectious disease are among the most frequently visited tourist destinations. The SEIMC considers it appropriate to produce a consensus document that will be useful to primary care physicians as well as specialists in internal medicine, infectious diseases and tropical medicine who help treat travelers returning from tropical and sub-tropical areas with infections. Preventive aspects of infectious diseases and infections imported by immigrants are explicitly excluded here, since they have been dealt with in other SEIMC documents. Various types of professionals (clinicians, microbiologists, and parasitologists) have helped produce this consensus document by evaluating the available evidence-based data in order to propose a series of key facts about individual aspects of the topic. The first section of the document is a summary of some of the general aspects concerning the general assessment of travelers who return home with potential infections. The main second section contains the key facts (causative agents, diagnostic procedures and therapeutic measures) associated with the major infectious syndromes affecting returned travelers [gastrointestinal syndrome (acute or persistent diarrhea); febrile syndrome with no obvious source of infection; localized cutaneous lesions; and respiratory infections]. Finally, the characteristics of special traveler subtypes, such as pregnant women and immunocompromised travelers, are described (AU)
En el mundo global, el conocimiento de las enfermedades infecciosas importadas es esencial en la práctica diaria, tanto para el microbiólogo-parasitólogo como para el clínico en enfermedades infecciosas que atiende a viajeros internacionales. Entre los destinos turísticos más visitados se encuentran muchos países tropicales o subtropicales, donde el riesgo de contraer una enfermedad infecciosa es más elevado. La SEIMC ha considerado pertinente la elaboración de un documento de consenso que sirva de ayuda tanto a médicos de Atención Primaria como a especialistas en Medicina Interna, Enfermedades Infecciosas y Medicina Tropical que atienden a viajeros que regresan con infecciones tras un viaje a zonas tropicales y subtropicales. Se han excluido de forma explícita los aspectos de prevención de estas y las infecciones importadas por inmigrantes, objeto de otros documentos de la SEIMC. Varios tipos de profesionales (clínicos, microbiólogos y parasitólogos) han desarrollado este documento de consenso tras evaluar los datos disponibles basados en la evidencia para proponer una serie de datos clave acerca de este aspecto. Inicialmente se revisan los aspectos generales acerca de la evaluación general del viajero que regresa con una potencial infección. En un segundo bloque se señalan los datos clave (agentes causales, procedimientos diagnósticos y medidas terapéuticas) de los síndromes infecciosos principales en el viajero que regresa (síndrome gastrointestinal (diarrea aguda o persistente), síndrome febril sin foco aparente, lesiones cutáneas localizadas e infecciones respiratorias). Finalmente se describen las características en viajeros especiales como la viajera embarazada y el viajero inmunodeprimido (AU)
Subject(s)
Humans , Male , Female , Communicable Diseases/epidemiology , Communicable Diseases/microbiology , Consensus , Eosinophilia/epidemiology , Nervous System Diseases/epidemiology , Societies, Medical/organization & administration , Societies, Medical/standards , Microbiology , Microbiology/organization & administration , Travelers' Health , Travel Medicine/organization & administrationABSTRACT
In a global world, knowledge of imported infectious diseases is essential in daily practice, both for the microbiologist-parasitologist and the clinician who diagnoses and treats infectious diseases in returned travelers. Tropical and subtropical countries where there is a greater risk of contracting an infectious disease are among the most frequently visited tourist destinations. The SEIMC considers it appropriate to produce a consensus document that will be useful to primary care physicians as well as specialists in internal medicine, infectious diseases and tropical medicine who help treat travelers returning from tropical and sub-tropical areas with infections. Preventive aspects of infectious diseases and infections imported by immigrants are explicitly excluded here, since they have been dealt with in other SEIMC documents. Various types of professionals (clinicians, microbiologists, and parasitologists) have helped produce this consensus document by evaluating the available evidence-based data in order to propose a series of key facts about individual aspects of the topic. The first section of the document is a summary of some of the general aspects concerning the general assessment of travelers who return home with potential infections. The main second section contains the key facts (causative agents, diagnostic procedures and therapeutic measures) associated with the major infectious syndromes affecting returned travelers [gastrointestinal syndrome (acute or persistent diarrhea); febrile syndrome with no obvious source of infection; localized cutaneous lesions; and respiratory infections]. Finally, the characteristics of special traveler subtypes, such as pregnant women and immunocompromised travelers, are described.
Subject(s)
Communicable Diseases, Imported/diagnosis , Communicable Diseases, Imported/therapy , Humans , TravelABSTRACT
Los helmintos presentes en el suelo, Ascaris lumbricoides, Trichuris trichiura, uncinarias (Ancylostoma duodenale y Necator americanus) y Strongyloides stercoralis, infestan a millones de personas que habitan sobre todo en áreas rurales y deprimidas de regiones tropicales y subtropicales. Los grandes flujos migratorios han facilitado su extensión a todo el mundo. Además de ser debilitantes y causar una mortalidad significativa, conllevan una alta morbilidad y afectan al desarrollo físico e intelectual de millones de niños que viven en áreas deprimidas. Junto con los benzimidazoles albendazol y mebendazol, las campañas internacionales de prevención y tratamiento a gran escala, han conseguido disminuir el número de afectados, pero la reinfestación y la resistencia a los benzimidazoles son frecuentes, por lo que es muy aconsejable mantener la atención sobre estos parásitos olvidados
Millions of people in in rural areas and deprived tropical and subtropical regions are infected by soil-transmitted helminths: Ascaris lumbricoides, Trichuris trichiura, hookworms (Ancylostoma duodenaleand Necator americanus), and Strongyloides stercoralis. Large migratory flows have made their worldwide distribution easier. Besides being debilitating and producing a significant mortality, they cause high morbidity, leading to physical and intellectual impairment in millions of children who live in poverty. Along with the use of benzimidazoles (albendazole and mebendazole), large-scale international campaigns for treatment and prevention have decreased the number of affected individuals. However, re-infestations and benzimidazole-resistance are frequent, so there needs to be awareness about the importance and consequences of these neglected parasites
Subject(s)
Humans , Helminths/isolation & purification , Soil Microbiology , Soil Analysis , Environmental Pollution , Myiasis/epidemiology , Poverty Areas , Trichuriasis/epidemiology , Hookworm Infections/epidemiology , Strongyloidiasis/epidemiologyABSTRACT
La malaria es, globalmente, la enfermedad parasitaria más importante, representando un problema de salud pública en más de 90 países. En los últimos años se ha observado un aumento en la incidencia de las complicaciones pulmonares. Su forma clínica más grave es el síndrome de distrés respiratorio agudo, que tiene una elevada mortalidad a pesar de un adecuado abordaje terapéutico. Se presenta como un cuadro de disnea súbita, tos e hipoxemia refractaria, requiriendo ingreso en unidades de cuidados intensivos, tratamiento antipalúdico parenteral precoz, y soporte ventilatorio y hemodinámico. Todo paciente con malaria que presente disnea requiere vigilancia estrecha, ya que el desarrollo de distrés respiratorio es un factor de mal pronóstico (AU)
Malaria is the most important parasitic disease worldwide, being a public health challenge in more than 90 countries. The incidence of pulmonary manifestations has increased in recent years. Acute respiratory distress syndrome is the most severe form within the pulmonary complications of malaria, with high mortality despite proper management. This syndrome manifests with sudden dyspnoea, cough and refractory hypoxaemia. Patients should be admitted to intensive care units and treated with parenteral antimalarial drug treatment and ventilatory and haemodynamic support without delay. Therefore, dyspnoea in patients with malaria should alert clinicians, as the development of respiratory distress is a poor prognostic factor (AU)
Subject(s)
Humans , Male , Female , Malaria/complications , Malaria/epidemiology , Malaria/prevention & control , Dyspnea/complications , Antimalarials/therapeutic use , Plasmodium falciparum/isolation & purification , Radiography, Thoracic/methods , Respiratory Tract Diseases/complications , Respiratory Tract Infections/complications , Pulmonary Edema/complications , Respiration, Artificial/methods , Respiration, Artificial , PrognosisABSTRACT
Millions of people in in rural areas and deprived tropical and subtropical regions are infected by soil-transmitted helminths: Ascaris lumbricoides, Trichuris trichiura, hookworms (Ancylostoma duodenale and Necator americanus), and Strongyloides stercoralis. Large migratory flows have made their worldwide distribution easier. Besides being debilitating and producing a significant mortality, they cause high morbidity, leading to physical and intellectual impairment in millions of children who live in poverty. Along with the use of benzimidazoles (albendazole and mebendazole), large-scale international campaigns for treatment and prevention have decreased the number of affected individuals. However, re-infestations and benzimidazole-resistance are frequent, so there needs to be awareness about the importance and consequences of these neglected parasites.
Subject(s)
Helminthiasis , Soil/parasitology , Vulnerable Populations/statistics & numerical data , Ancylostoma , Ancylostomatoidea , Animals , Ascaris lumbricoides , Helminthiasis/diagnosis , Helminthiasis/epidemiology , Helminthiasis/therapy , Helminthiasis/transmission , Humans , Necator americanus , Rural Population , Trichuris , Tropical ClimateABSTRACT
Malaria is the most important parasitic disease worldwide, being a public health challenge in more than 90 countries. The incidence of pulmonary manifestations has increased in recent years. Acute respiratory distress syndrome is the most severe form within the pulmonary complications of malaria, with high mortality despite proper management. This syndrome manifests with sudden dyspnoea, cough and refractory hypoxaemia. Patients should be admitted to intensive care units and treated with parenteral antimalarial drug treatment and ventilatory and haemodynamic support without delay. Therefore, dyspnoea in patients with malaria should alert clinicians, as the development of respiratory distress is a poor prognostic factor.
Subject(s)
Malaria, Falciparum/complications , Respiratory Distress Syndrome/parasitology , Combined Modality Therapy , Humans , Prognosis , Respiratory Distress Syndrome/diagnosis , Respiratory Distress Syndrome/mortality , Respiratory Distress Syndrome/therapyABSTRACT
La podoconiosis, o «elefantiasis endémica no filariásica», es una enfermedad geoquímica que produce un tipo de linfedema de los miembros inferiores relacionado directamente con caminar descalzo por terrenos de origen volcánico en áreas con un alto índice pluviométrico anual. Posee una distribución geográfica concreta, afecta aproximadamente a un 5% de la población de las áreas endémicas, es debilitadora y desfigurante y con frecuencia lleva a la marginación social de los que la sufren. Es una enfermedad prevenible y, una vez establecida, puede mejorar con medidas terapéuticas sencillas (AU)
Podoconiosis, mossy foot or endemic non-filarial elephantiasis, is a geochemical disease that causes lower limb lymphedema; it is directly related to walking barefoot over soils of volcanic origin, in areas with a high pluviometric annual index. It has a specific geographical distribution, affecting around 5% population in areas where it is endemic. It is debilitating and disfiguring disease, which frequently leads to social margination. Podoconiosis is totally preventable and, once a diagnosis is established, it may improve with simple therapeutic measures (AU)
Subject(s)
Female , Humans , Male , Hyperkeratosis, Epidermolytic/metabolism , Hyperkeratosis, Epidermolytic/pathology , Primary Prevention/education , Primary Prevention/methods , Geology/economics , Geology/history , Epidemiology/economics , Guatemala/ethnology , Africa/ethnology , Hyperkeratosis, Epidermolytic/complications , Hyperkeratosis, Epidermolytic/diagnosis , Primary Prevention , Primary Prevention/standards , Geology/classification , Geology/statistics & numerical data , Epidemiology/statistics & numerical data , Guatemala/epidemiology , Africa/epidemiologyABSTRACT
Podoconiosis, mossy foot or endemic non-filarial elephantiasis, is a geochemical disease that causes lower limb lymphedema; it is directly related to walking barefoot over soils of volcanic origin, in areas with a high pluviometric annual index. It has a specific geographical distribution, affecting around 5% population in areas where it is endemic. It is debilitating and disfiguring disease, which frequently leads to social margination. Podoconiosis is totally preventable and, once a diagnosis is established, it may improve with simple therapeutic measures.
Subject(s)
Elephantiasis , Neglected Diseases , Diagnosis, Differential , Elephantiasis/diagnosis , Elephantiasis/epidemiology , Elephantiasis/etiology , Elephantiasis/therapy , Global Health , Humans , Neglected Diseases/diagnosis , Neglected Diseases/epidemiology , Neglected Diseases/etiology , Neglected Diseases/therapy , Risk FactorsABSTRACT
No disponible
